With LentiGlobin cleared by FDA, bluebird lifts EU marketing hold on gene therapy using the same delivery mechanism

With the FDA finally off its back on its LentiGlobin sickle cell program, bluebird bio is heading into its big split-up with a mostly clear path for its rare disease unit. The one remaining hang-up was the status of the beta thalassemia gene therapy Zynteglo in the EU, but bluebird’s flight path now seems clear there, too.